Galecto begins third phase II trial

The first patient has now received a dose of Galecto's drug candidate GB1211 in a crucial phase 1b/2a trial meant to assess its efficacy in treating liver cirrhosis.
Hans Schambye, president and CEO at Galecto. | Photo: Henriette Dan Bonde / PR
Hans Schambye, president and CEO at Galecto. | Photo: Henriette Dan Bonde / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

With the first dose administered, Galecto has now begun a third phase II trial – specifically a 1b/2a trial. The substance is being tested as a treatment for liver cirrhosis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading